CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with the German pharmaceutical and chemical giant Merck KGaA (FRA: MRK). The agreement pertains to CybernaX’s proprietary technology for efficient lipid storage. While the financial details of the transaction remain undisclosed, the partnership signals a significant move in the mRNA encapsulation and delivery space.
CybernaX’s lipids are recognized for their efficient mRNA encapsulation and delivery, ensuring good safety profiles and the ability to selectively deliver to non-liver targets. This collaboration is poised to bolster Merck’s competitive edge in mRNA targeted delivery solutions, which utilize lipid nanoparticles. The alliance aims to push the frontiers of next-generation lipid nanoparticles and nucleic acid drugs, potentially revolutionizing the landscape of targeted therapeutics.- Flcube.com
